Menu Search
Equities

Surgical Science Sweden AB

SUS:STO

Surgical Science Sweden AB

Actions
  • Price (SEK)145.80
  • Today's Change-0.300 / -0.21%
  • Shares traded23.20k
  • 1 Year change-9.72%
  • Beta1.2523
Data delayed at least 15 minutes, as of Nov 22 2024 11:33 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy2
Outperform3
Hold0
Sell0
Strong Sell0

Share price forecast in SEK

The 5 analysts offering 12 month price targets for Surgical Science Sweden AB have a median target of 183.00, with a high estimate of 225.00 and a low estimate of 165.00. The median estimate represents a 25.26% increase from the last price of 146.10.
High54.0%225.00
Med25.3%183.00
Low12.9%165.00

Earnings history & estimates in SEK

On Nov 14, 2024, Surgical Science Sweden AB reported 3rd quarter 2024 earnings of 0.84 per share. This result exceeded the 0.71 consensus of the 4 analysts covering the company and under-performed last year's 3rd quarter results by 9.68%.
The next earnings announcement is expected on Feb 19, 2025.
Average growth rate+25.02%
Surgical Science Sweden AB reported annual 2023 earnings of 4.59 per share on Feb 21, 2024.
Average growth rate+114.91%
More ▼

Revenue history & estimates in SEK

Surgical Science Sweden AB (publ) had 3rd quarter 2024 revenues of 231.83m. This bettered the 230.25m consensus of the 4 analysts covering the company. This was 1.20% above the prior year's 3rd quarter results.
Average growth rate+3.23%
Surgical Science Sweden AB (publ) had revenues for the full year 2023 of 882.85m. This was 10.01% above the prior year's results.
Average growth rate+95.51%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.